Shenzhen Salubris Pharmaceuticals (002294) Q2 2025 earnings summary

Executive summary

• Achieved revenue of ¥2.13 billion, up 4.32% year-over-year; net profit attributable to shareholders was ¥365 million, up 6.10% year-over-year.

• Second quarter revenue grew 12.30% and net profit rose 14.55% year-over-year.

• New product launches and patent-protected drugs drove significant sales growth, becoming core performance drivers.

• R&D investment reached ¥542 million, accounting for 25.43% of revenue.

• Two new cardiovascular drugs, 信超妥 and 复立安®, were approved and launched.

Financial highlights

• Operating income: ¥2,130,967,669.97, up 4.32% year-over-year.

• Net profit attributable to shareholders: ¥365,078,698.05, up 6.10% year-over-year.

• Net profit excluding non-recurring items: ¥346,830,164.52, up 3.93% year-over-year.

• Operating cash flow: ¥425,428,003.38, down 20.19% year-over-year.

• Basic and diluted EPS: ¥0.33, up from ¥0.31 year-over-year.

• Gross margin for pharmaceutical manufacturing: 75.61%, up 3.58 percentage points.

Outlook and guidance

• Focus on expanding innovative product pipeline in cardiovascular, renal, metabolic, and orthopedic fields.

• Multiple late-stage clinical projects expected to reach key milestones or market entry in the next few years.

• Continued investment in R&D and new technology platforms to drive long-term growth.